Connect with us
This summer, Exheus has received an Enisa loan amounting to $236,000 (€200,000). This is a long-term loan issued by the Ministry and offers extended repayment and...
ExeVir is a spin-off of VIB and is headed by German Dr. Torsten Mummenbrauer, a virologist who has worked for GSK Morphosys, Hookipa Pharma and Velvio....
Grifols has assured that 87.93% of bondholders of its secured bonds, 81.01% of unsecured bonds, the required 93.82% of underwriters of its syndicated credit facility, and...
Valneva will soon be able to sell its Covid-19 vaccine candidate. On the European side, Valneva has broken off negotiations with the European Commission, preferring bilateral...
Before being authorized, the vaccine developed by Hipra will have to pass stage I/II, where its safety will have to be demonstrated. Phase III will then...
Gilead's peak revenue in Spain was in 2015 when the company had a turnover $1.15 billion (€978.5 million). Those figures were due to the commercialization of...
The biotech company Sinovac announced that it plans to build a vaccine manufacturing facility in Chile. Minister of Health, Enrique Paris, also detailed that the vaccines...
Incliva participates in the $6.2 million (€5.2 million) European Rebecca project to address the post-treatment of breast cancer. The project will end in March 2025 and...
Grifols, which specializes in the production of plasma derivatives, achieved a profit of $317.2 million (€266.8 million) in the first half of 2021, which translates into...
Grifols increases its profits in the first six months of the year. The Spanish multinational, which specializes in the production of plasma derivatives, achieved a profit...
 |
|
 |  |
 |
|